The global Gynecological Cancer Drugs Market Size was valued at $11.6 billion in 2020 and is projected to reach $21.8 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030.
Gynecological Cancer refers to a group of cancers that affect the reproductive organs of a female such as an endometrium, uterus, peritoneum, ovary, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus. Cancer is a specific disorder that can cause abnormal cell growth in any part of the body. Cancer is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female.
The key factors that drive the Gynecological Cancer Drugs Market Growth are the rise in the incidence of gynecological cancers and an increase in investment from the government, public, &private sectors for cancer treatment are the key factors that drive the growth of the market. In addition, an increase in product approval is the key factor that is anticipated to drive the growth of the market in upcoming years. For instance, in November 2020, European Union (EU) approved Lynparza treatment with bevacizumab for homologous recombination deficient (HRD)-positive advanced ovarian cancer. In addition, the surge in cancer awareness and early screening of cancer also contribute to the growth of the Gynecological Cancer Drugs Industry. However, the high cost involved in new drug development coupled with the threat of failure & adverse effects associated with gynecological cancer drugs therapies poses to restrain the growth of the gynecological cancer drugs market. Conversely, the high potential of emerging economies and a higher number of potential drugs in the pipeline are the Gynecological Cancer Drugs Market Opportunity.
The Gynecological Cancer Drugs Industry is segmented by therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Therapeutic Modality Segment Review
The Targeted Therapy segment is expected to lead the market throughout the forecast period.
By Therapeutic Modality
Depending on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The targeted therapy generated the highest revenue in 2020. Owing to the adoption of target therapy across the world, targeted therapy offers many advantages as it interferes with specific proteins involved in tumorigenesis focusing on specific molecular changes, which stop the growth of various types of cancers. Major factors that influenced the gynecology cancer drugs market growth include the fewer adverse effects of the therapy and the availability of a number of targeted therapeutics.
Indication Segment Review
The Cervical Cancer segment is expected to lead the market throughout the forecast period.
By Indication
By indication, the indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. The cervical cancer segment dominated the market in 2020, and this trend is expected to continue during the forecast period. As HPV is the major causative agent for cervical cancer, thus HPV vaccine is used in most of the developed regions of the world for the prevention against the disease.
Region Segment Review
Region-wise, North America dominated the Gynecological Cancer Drugs Market Share in 2020 and is expected to be dominant during the forecast period, owing to the presence of large patient population, strong presence of key players, ease of drug availability, well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, arise in research and development, & innovation activities and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to grow at the highest CAGR, owing to an increase in the number of cancer-affected populations and a rise in awareness related to different cancers.
The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gynecological cancer drugs market analysis from 2020 to 2030 to identify the prevailing gynecological cancer drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the gynecological cancer drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global gynecological cancer drugs market trends, key players, market segments, application areas, and market growth strategies.
Gynecological Cancer Drugs Market Report Highlights
| Aspects | Details |
 By Indication |
|
 By Therapeutic Modality |
|
 By Region |
|
 Key Market Players | PFIZER INC, MERCK & CO., INC, GLAXOSMITHKLINE PLC, TEVA PHARMACEUTICAL INDUSTRIES LTD, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD, APOTEX INC, BRISTOL-MYERS SQUIBB COMPANY, ASTRAZENECA PLC, ELI LILLY AND COMPANY |
Analyst Review
According to the CXOs, the adoption of gynecological cancer drugs is expected to increase in the near future, owing to a high prevalence rate of gynecological cancers globally. The gynecological cancer drugs market has piqued the interest of healthcare providers owing to continuous R&D in the field of oncology drugs.This has led to the emergence of new treatment options for patients suffering from cancer. In addition, increase ininvestment from various organizations for cancer treatment and surge in risk factors that further drive the market growth.
According to the perspective of CXOs, North America is expected to dominate the global gynecological cancer drugsmarket during the forecast period, followed by Europe. In addition, Asia-Pacific and LAMEA are expected to offerlucrative opportunities to market players throughout the forecast period.
The total market value of the Gynecological Cancer Drugs market is $11,622.5 million in 2020
$21,791.44 million is the estimated industry size for Gynecological Cancer Drugs in 2030
The upcoming trends of the Gynecological Cancer Drugs Market are high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sector for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth
North America is the largest regional market for Gynecological Cancer Drugs
Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG are the top companies to hold the market share in Gynecological Cancer Drugs
Loading Table Of Content...
